Replicate Bioscience

Andrew Geall

Chief Development Officer
Replicate Bioscience
  • Replicate is a clinical stage company with end-to-end development capabilities at its disposal.
  • Replicate‚Äôs platform leverages next-generation self-replicating RNA (srRNA) vectors. Once inside cells, the genetic code of our srRNA drives repeated production of natural RNA, resulting in outsized protein expression and durable therapeutic effect.
  • Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas, including infectious disease, oncology, and autoimmune disorders. Improved performance over linear mRNA lets us help even more patients.